Axsome Therapeutics (AXSM) Projected to Post Quarterly Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) is expected to issue its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Axsome Therapeutics to announce earnings of ($0.8921) per share and revenue of $221.1140 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 8:00 AM ET.

Axsome Therapeutics Price Performance

AXSM stock opened at $212.74 on Friday. The stock has a 50-day moving average price of $236.95 and a two-hundred day moving average price of $203.96. Axsome Therapeutics has a 12-month low of $102.67 and a 12-month high of $260.19. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The company has a market cap of $10.95 billion, a PE ratio of -57.03 and a beta of 0.65.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AXSM. Deutsche Bank Aktiengesellschaft set a $280.00 target price on Axsome Therapeutics in a report on Tuesday, May 5th. Royal Bank Of Canada boosted their price objective on shares of Axsome Therapeutics from $302.00 to $304.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Piper Sandler reaffirmed an “overweight” rating and set a $258.00 price target on shares of Axsome Therapeutics in a research report on Monday, May 4th. Truist Financial raised Axsome Therapeutics to a “strong-buy” rating in a research report on Monday, June 15th. Finally, Guggenheim upped their target price on Axsome Therapeutics from $245.00 to $260.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $265.55.

Insiders Place Their Bets

In other Axsome Therapeutics news, Director Mark Coleman sold 643 shares of the firm’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $249.00, for a total transaction of $160,107.00. Following the completion of the transaction, the director directly owned 30,389 shares of the company’s stock, valued at $7,566,861. This trade represents a 2.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roger Jeffs sold 286 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $246.18, for a total transaction of $70,407.48. Following the completion of the sale, the director directly owned 58,653 shares of the company’s stock, valued at $14,439,195.54. The trade was a 0.49% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 200,766 shares of company stock valued at $46,685,646. 20.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Axsome Therapeutics

A number of hedge funds have recently bought and sold shares of AXSM. Kemnay Advisory Services Inc. acquired a new stake in Axsome Therapeutics during the fourth quarter valued at approximately $31,000. Ameriflex Group Inc. bought a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $37,000. Advisory Services Network LLC bought a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at approximately $40,000. Johnson Financial Group Inc. acquired a new stake in shares of Axsome Therapeutics during the 3rd quarter valued at approximately $61,000. Finally, Strive Financial Group LLC acquired a new stake in shares of Axsome Therapeutics during the 4th quarter valued at approximately $62,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.